Adrenal Disease
Conditions
Brief summary
As a vital organ responsible for producing life-sustaining hormones, the adrenal gland is associated with a wide range of diseases. These diseases affect multiple systems throughout the body and carry a high rate of mortality and disability. Current diagnosis and treatment face several challenges: significant variability in hormone testing results, inaccurate localization via imaging techniques, unclear molecular characteristics of adrenal tumors, and difficulty in determining prognosis through pathology. Therefore, establishing a clinical research cohort for adrenal diseases is essential. Such a cohort will enable in-depth exploration of disease mechanisms, identification of disease subtypes, optimization of diagnostic criteria, evaluation of treatment efficacy, advancement of personalized medicine, and formulation of prevention and treatment strategies.
Interventions
OTHERReceive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RenJi Hospital
Shanghai Zhongshan Hospital
Shanghai Public Health Clinical Center
Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* A signed and dated informed consent form * Commitment to abide by the study procedures and cooperate with the implementation of the entire study process * Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy * Aged between 18 and 75 years
Exclusion criteria
* Subjects meeting any of the following criteria will be excluded from this study: * Refuse to sign the informed consent form * Patients without adrenal diseases * Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-Treatment Remission Rate | at least six months or more |
| Treatment Response Rate | at least six months or more |
Countries
China
Contacts
Primary ContactYiran Jiang
Outcome results
None listed